Notably, clinical trials have demonstrated the efficacy of Trop2-targeted ADCs, including SG, in treating breast cancer (TNBC and HR+ breast cancer) and urothelial cancer, leading to FDA approval of SG for these two cancer types (12–14). This evidence concerns the gene TACSTD2 and breast carcinoma.